Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1517/13543784.2015.1021919 http://scihub22266oqcxt.onion/10.1517/13543784.2015.1021919 C4433440!4433440 !25727893     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=25727893 &cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\25727893 .jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117       Expert+Opin+Investig+Drugs 2015 ; 24 (6 ): 743-60 Nephropedia Template TP {{tp|p=25727893 |t=2015. Investigational agents for treatment of traumatic brain injury |pdf=|usr=}}{{25727893 }} gab.com Text Investigational agents for treatment of traumatic brain injury JO: Expert Opin Investig Drugs http://www.kidney.de/pget.php?&tw=1&pmid=25727893 #FOAvip INTRODUCTION: Traumatic brain injury (TBI) is a major cause of death and disability worldwide. To date, there are no pharmacologic agents proven to improve outcomes from TBI because all the Phase III clinical trials in TBI have failed. Thus, there is a compelling need to develop treatments for TBI. AREAS COVERED: The following article provides an overview of select cell-based and pharmacological therapies under early development for the treatment of TBI. These therapies seek to enhance cognitive and neurological functional recovery through neuroprotective and neurorestorative strategies. EXPERT OPINION: TBI elicits both complex degenerative and regenerative tissue responses in the brain. TBI can lead to cognitive, behavioral, and motor deficits. Although numerous promising neuroprotective treatment options have emerged from preclinical studies that mainly target the lesion, translation of preclinical effective neuroprotective drugs to clinical trials has proven challenging. Accumulating evidence indicates that the mammalian brain has a significant, albeit limited, capacity for both structural and functional plasticity, as well as regeneration essential for spontaneous functional recovery after injury. A new therapeutic approach is to stimulate neurovascular remodeling by enhancing angiogenesis, neurogenesis, oligodendrogenesis, and axonal sprouting, which in concert, may improve neurological functional recovery after TBI. Twit Text FOAVip Investigational agents for treatment of traumatic brain injury ????Expert Opin Investig Drugs http://www.kidney.de/pget.php?&tw=1&pmid=25727893 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=25727893 #FOAvip English Wikipedia <ref>{{Cite pmid|25727893 }}</ref> Investigational agents for treatment of traumatic brain injury #MMPMID25727893 Xiong Y ; Zhang Y ; Mahmood A ; Chopp M Expert Opin Investig Drugs 2015[Jun]; 24 (6 ): 743-60 PMID25727893 show ga INTRODUCTION: Traumatic brain injury (TBI) is a major cause of death and disability worldwide. To date, there are no pharmacologic agents proven to improve outcomes from TBI because all the Phase III clinical trials in TBI have failed. Thus, there is a compelling need to develop treatments for TBI. AREAS COVERED: The following article provides an overview of select cell-based and pharmacological therapies under early development for the treatment of TBI. These therapies seek to enhance cognitive and neurological functional recovery through neuroprotective and neurorestorative strategies. EXPERT OPINION: TBI elicits both complex degenerative and regenerative tissue responses in the brain. TBI can lead to cognitive, behavioral, and motor deficits. Although numerous promising neuroprotective treatment options have emerged from preclinical studies that mainly target the lesion, translation of preclinical effective neuroprotective drugs to clinical trials has proven challenging. Accumulating evidence indicates that the mammalian brain has a significant, albeit limited, capacity for both structural and functional plasticity, as well as regeneration essential for spontaneous functional recovery after injury. A new therapeutic approach is to stimulate neurovascular remodeling by enhancing angiogenesis, neurogenesis, oligodendrogenesis, and axonal sprouting, which in concert, may improve neurological functional recovery after TBI. |Animals [MESH] |Brain Injuries/*drug therapy/physiopathology [MESH] |Clinical Trials as Topic [MESH] |Drug Design [MESH] |Drug Evaluation, Preclinical [MESH] |Drugs, Investigational/pharmacology/*therapeutic use [MESH] |Humans [MESH] |Molecular Targeted Therapy [MESH] |Neurogenesis/drug effects [MESH]Investigational agents for treatment of traumatic brain injury (epmc).pdf DeepDyve Pubget Overpricing